473734-47-3

Upstream product

• 1356349-74-0 tert-butyl [(2S)-1-cyclopentylpropan-2-yl]carbamate 

Downstream Products

• 1356349-77-3 (2S)-1-cyclopentyl-N-(5-fluoro-2-nitrobenzyl)propan-2-amine 
• 1356349-42-2 N-[2-({[(2S)-1-cyclopentylpropan-2-yl]amino}methyl)-4-fluorophenyl]-8-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide 
• 1356349-79-5 tert-butyl [(2S)-1-cyclopentylpropan-2-yl](5-fluoro-2-nitrobenzyl)carbamate 
• 1356349-81-9 tert-butyl (2-amino-5-fluorobenzyl)[(2S)-1-cyclopentylpropan-2-yl]carbamate 
• 1356349-83-1 tert-butyl [(2S)-1-cyclopentylpropan-2-yl](5-fluoro-2-{[(8-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)sulfonyl]amino}benzyl)carbamate 

Relevant academic research and scientific papers

HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS

The present invention provides aromatic sulphonamides as tRNA synthetase inhibitors and process for their synthesis, pharmaceutical composition and method for treatment. Compounds disclosed can be used as antibacterial agents for the treatment or prevention of conditions caused by or contributed by aerobic and anaerobic Gram-positive pathogens, more particularly against bacterium, for example Staphylococcus, Enterococci and Streptococci. Compounds disclosed are used in particular for the treatment of skin and soft tissue infection, Formula (I)

Asymmetric intermolecular hydroamination of unactivated alkenes with simple amines

A hard nut to crack: The asymmetric intermolecular Markovnikov addition of simple amines to unactivated alkenes can be achieved utilizing binaphtholate rare-earth-metal catalysts with up to 61% ee and 73% de in the case where R 2 contains a stereogenic center.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.